Overview

• Negotiations with the Association of the British Pharmaceutical Industry ended Friday without changes to the voluntary cap‑and‑rebate framework.
• Wes Streeting said he would not let “big pharma” “rip off” patients or taxpayers and called companies “shortsighted.”
• The government says its offer would have lowered payment rates and freed about £1bn over three years, while companies forecast paying back roughly £13.5bn in that period.
• ABPI argues UK clawbacks are far higher than in comparable European markets and warns firms may shift trials, jobs and investment away from Britain.
• Gilead said it will not submit a new breast cancer medicine to NICE as industry challenges NICE’s £20,000–£30,000 per‑QALY threshold that Streeting defends.